about
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesClinical studies with anti-CTLA-4 antibodies in non-melanoma indications.Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.Armed antibodies for cancer treatment: a promising tool in a changing era.Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.Immunotherapy targeting immune check-point(s) in brain metastases.Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.False Leser-Trélat sign
P50
Q33396664-9AF23ABC-9BEA-423D-A548-9D075C384275Q33643902-134C79DB-20C8-4A9D-AA58-59ECDAF6BAC1Q33980682-66C73EE2-F33D-4F19-B935-139FCB293F0AQ37809154-03841F70-1CBF-46C2-BEC7-E652DFBDCB9BQ38050835-D257D38A-9C96-491F-B80D-40B9479D53E3Q38260165-8F8CB160-3240-4C42-AC08-1FDAAE12B105Q38475150-416E625D-AF97-4F41-A255-CF425C2624DBQ39247530-23C506A3-8253-4141-90C1-3674A5CF1D25Q39453143-8F4A8BA1-F7B4-4F0A-BA1E-6101C05912C4Q39500230-001AF2EA-EF0E-4A89-B48D-95688F6B0884Q39873712-D9F22F54-817E-48B1-AAEF-0863BFC2580AQ40163076-12E275A8-9AFA-4385-9914-FFC558A879FCQ40479861-5BFE4BC9-00B0-4104-A637-6C55B38FB296Q41740586-05B926CC-32CB-4D9D-BF93-E50D8E00C899Q43176112-4329826A-FACE-475E-828F-AA6BFE4D4DFAQ44807139-E89C64F1-63CC-41B7-AC16-09C84D51F73AQ48401064-43A3082C-8D11-4EB2-AA26-334AD814EE3DQ50147228-669F6E30-1CDF-4EF8-AA9E-99D32788E451Q50191687-4FD8F59B-9001-46DD-A9DC-91415FEB4E03Q50934997-C3A7A17B-03D3-47F5-9D44-50929DE0F94DQ51738566-52FEB7A2-B2AD-41E7-9DEF-C440142EF702Q52758918-9C888A7A-FC6F-47F4-B650-792DD0F89456Q52777255-3439E739-8FAE-4A87-A4E5-EBAD8A11FFE0Q84360907-558F32F4-4D87-4FE8-BFA0-DC8E92555DD5
P50
description
researcher ORCID ID = 0000-0002-7363-5512
@en
wetenschapper
@nl
name
Riccardo Danielli
@ast
Riccardo Danielli
@en
Riccardo Danielli
@es
Riccardo Danielli
@nl
type
label
Riccardo Danielli
@ast
Riccardo Danielli
@en
Riccardo Danielli
@es
Riccardo Danielli
@nl
prefLabel
Riccardo Danielli
@ast
Riccardo Danielli
@en
Riccardo Danielli
@es
Riccardo Danielli
@nl
P106
P1153
8915257500
P31
P496
0000-0002-7363-5512